# OnCo record precise-mrd (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/precise-mrd/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "precise-mrd" ;
  schema:name "Precise MRD"@en ;
  schema:alternateName "Myriad Precise MRD"@en, "Precise MRD" ;
  schema:description "Myriad Genetics' whole-genome blood test for leftover cancer, launched in 2026 for breast cancer and extended to bowel and kidney cancer."@en ;
  schema:url <https://onco.cc/drugs/precise-mrd/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://investor.myriad.com/news-releases/news-release-detail/27031/>, <https://investor.myriad.com/news-releases/news-release-detail/27436/>, <https://myriad.com/oncology/precise-mrd-test/>, <https://doi.org/10.1080/14796694.2026.2690165> ;
  onco:status "emerging" ;
  onco:tag "test" ;
  onco:modality "Tumour-informed whole-genome ctDNA minimal residual disease test (up to 1,000 variants)" ;
  onco:related <https://onco.cc/drugs/next-personal/>, <https://onco.cc/drugs/signatera/> ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/wes-wgs/> ;
  onco:companies <https://onco.cc/companies/myriad-genetics/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tumour-informed-assay/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-monitor-breast-foldi-future-oncol-2026/> .